Origins and perspectives of the schizophrenia research;A szkizofréniakutatás kezdetei és perspektívái

Neuropsychopharmacologia Hungarica

Volumn 13, Issue 4, 2011, Pages 185-192

  Faludi, Gabor ^a   Dome, Peter ^a   Lazary, Judit ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Epidemiology; Etiology; Pathomechanism; Schizophrenia

Indexed keywords

DOPAMINE; SEROTONIN;

COMPUTER ASSISTED TOMOGRAPHY; DELUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENVIRONMENTAL FACTOR; GABAERGIC SYSTEM; HALLUCINATION; HERITABILITY; HUMAN; LIFE EXPECTANCY; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOMEDICAL RESEARCH; DOPAMINE; FETAL DEVELOPMENT; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; SCHIZOPHRENIA; SEROTONIN;

EID: 84858217174     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: 10.5706/nph201112001     Document Type: Review

References (38)

1. Arnt, J., Skarsfeldt, T. (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology, 18:63-101.
2. Bale, T. L., Baram, T. Z., Brown, A. S., Goldstein, J. M., Insel, T. R., McCarthy, M. M., Nemeroff, C. B., Reyes, T. M., Simerly, R. B., Susser, E. S., Nestler, E. J. (2011) Early life programming and neurodevelopmental disorders. Biological Psychiatry, 68:314-9.
3. Ban, T. A. (2007) Towards a clinical methodology for neuropsychopharmacological research. Neuropsychopharmacol Hung, 9:81-90.
4. Belforte, J. E., Zsiros, V., Sklar, E. R., Jiang, Z., Yu, G., Li, Y., Quinlan, E. M., Nakazawa, K. (2011) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature Neurosci, 13:76-83.
5. Buizer-Voskamp, J. E., Muntjewerff, J. W., Strengman, E., Sabatti, C., Stefansson, H., Vorstman, J. A., Ophoff, R. A. (2011) Genome-wide analysis shows increased frequency of copy number variation deletions in dutch schizophrenia patients. Biol Psychiatry, 70:655-62.
6. Buka, S. L., Tsuang, M. T., Torrey, E. F., Klebanoff, M. A., Bernstein, D., Yolken, R. H. (2001) Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry, 58:1032-7.
7. Bundy, H., Stahl, D., MacCabe, J. H. (2011) A systematic review and meta-analysis of the fertility of patients with schizophrenia and their unaffected relatives. Acta Psychiatr Scand, 123:98-106.
8. Carlborg, A., Winnerback, K., Jonsson, E. G., Jokinen, J., Nordstrom, P. (2011) Suicide in schizophrenia. Exp Rev Neurotherap, 10:1153-64.
9. Davis, K. L., Kahn, R. S., Ko, G., Davidson, M. (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry, 148:1474-86.
10. DSM-IV-TR (1994) Diagnostic and Statistical Manual of Mental Disorders (Text revision). American Psychiatric Association.
11. Faludi, G., Mirnics, K. (2011) Synaptic changes in the brain of subjects with schizophrenia. Int J Dev Neurosci, 29:305-9.
12. Garbett, K., Gal-Chis, R., Gaszner, G., Lewis, D. A., Mirnics, K. (2008) Transcriptome alterations in the prefrontal cortex of subjects with schizophrenia who committed suicide. Neuropsychopharmacol Hung, 10:9-14.
13. Hirvonen, J., Hiet-aletal, J. (2011) Dysfunctional brain networks and genetic risk for schizophrenia: specific neurotransmitter systems. CNS Neurosci Therap, 17:89-96.
14. Hodgson, R., Wildgust, H. J., Bushe, C. J. (2010) Cancer and schizophrenia: is there a paradox? J Psychopharm (Oxford, England), 24:51-60.
15. Howes, O. D., Kapur, S. (2009) The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull, 35:549-62.
16. ICD-10 (1992) The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Description and Diagnostic Guideline. World Health Organization.
17. Kasckow, J., Felmet, K., Zisook, S. (2011) Managing suicide risk in patients with schizophrenia. CNS Drugs, 25:129-43.
18. Keri, S., Kelemen, O. (2008) [An objective method for the assessment of expressed emotions and symptoms during direct family transactions in schizophrenia]. Neuropsychopharmacol Hung, 10:5-8.
19. Larson, M. K., Walker, E. F., Compton, M. T. (2011) Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Exp Rev Neurotherap, 10:1347-59.
20. Lewis, C. M., Levinson, D. F., Wise, L. H., DeLisi, L. E., Straub, R. E., Hovatta, I., Williams, N. M., Schwab, S. G., Pulver, A. E., Faraone, S. V., Brzustowicz, L. M., Kaufmann, C. A., Garver, D. L., Gurling, H. M., Lindholm, E., Coon, H., Moises, H. W., Byerley, W., Shaw, S. H., Mesen, A., Sherrington, R., O'Neill, F. A., Walsh, D., Kendler, K. S., Ekelund, J., Paunio, T., Lonnqvist, J., Peltonen, L., O'Donovan, M. C., Owen, M. J., Wildenauer, D. B., Maier, W., Nestadt, G., Blouin, J. L., Antonarakis, S. E., Mowry, B. J., Silverman, J. M., Crowe, R. R., Cloninger, C. R., Tsuang, M. T., Malaspina, D., Harkavy-Friedman, J. M., Svrakic, D. M., Bassett, A. S., Holcomb, J., Kalsi, G., McQuillin, A., Brynjolfson, J., Sigmundsson, T., Petursson, H., Jazin, E., Zoega, T., Helgason, T. (2003) Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet, 73:34-48.
21. Lu, L., Mamiya, T., Koseki, T., Mouri, A., Nabeshima, T. (2011) Genetic animal models of schizophrenia related with the hypothesis of abnormal neurodevelopment. Biol Pharmacol Bull, 34:1358-63.
22. Makkos, Z., Fejes, L., Inczedy-Farkas, G., Kassai-Farkas, A., Faludi, G., Lazary, J. (2011) [Clinical characteristics of cannabisinduced schizophrenia spectrum disorder]. Neuropsychopharmacol Hung, 13:127-38.
23. McGrath, J., Saha, S., Chant, D., Welham, J. (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev, 30:67-76.
24. McGrath, J. J., Susser, E. S. (2009) New directions in the epidemiology of schizophrenia. Med J Aust, 190:S7-9.
25. Must, A., Janka, Z., Horvath, S. (2011) Schizophrenia, environment and epigenetics. Neuropsychopharmacol Hung, 13:211-218.
26. Nagai, T., Ibi, D., Yamada, K. (2011) Animal model for schizophrenia that reflects gene-environment interactions. Biol Pharm Bull, 34:1364-8.
27. Nedergaard, S., Bolam, J. P., Greenfield, S. A. (1988) Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nature, 333:174-7.
28. Rethelyi, J. (2011) From Bleuler to DSM-V: Diagnosing schizophrenia. Neuropsychopharmacol Hung, 13:193-204.
29. Saha, S., Chant, D. C., Welham, J. L., McGrath, J. J. (2006) The incidence and prevalence of schizophrenia varies with latitude. Acta Psychiat Scand, 114:36-9.
30. Schenkel, L. S., Silverstein, S. M. (2004) Dimensions of premorbid functioning in schizophrenia: a review of neuromotor, cognitive, social, and behavioral domains. Genetic, social, and general psychology monographs, 130:241-70.
31. Shin, J. K., Malone, D. T., Crosby, I. T., Capuano, B. (2011) Schizophrenia: a systematic review of the disease state, current therapeutics and their molecular mechanisms of action. Curr Med Chemistry, 18:1380-404.
32. Tenyi, T. (2011) Neurodevelopment and schizophrenia: data on minor physical anomalies and structural brain imaging. Neuropsychopharmacol Hung, 13:229-232.
33. Thompson, J. L., Urban, N., Abi-Dargham, A. (2009) How have developments in molecular imaging techniques furthered schizophrenia research? Imaging Med, 1:135-153.
34. Tsuang, M. T., Stone, W. S., Faraone, S. V. (2001) Genes, environment and schizophrenia. Br J Psychiatry, 40:s18-24.
35. Urfer-Parnas, A., Mortensen, E. L., Parnas, J. (2010) Core of schizophrenia: estrangement, dementia or neurocognitive disorder? Psychopathology, 43:300-11.
36. Vereczkei, A., Mirnics, K. (2011) Genetic predisposition to schizophrenia: what did we learn and what does the future hold? Neuropsychopharmacol Hung, 13:205-210.
37. Vollenweider, F. X., Vontobel, P., Oye, I., Hell, D., Leenders, K. L. (2000) Effects of (S)-ketamine on striatal dopamine: a [11C] raclopride PET study of a model psychosis in humans. J Psychiat Res, 34:35-43.
38. Wildgust, H. J., Beary, M. (2011) Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? Journal of Psychopharmacology (Oxford, England), 24:37-50.